From Our Blog
Here’s a Little of What We’ve Learned Over the Years!
April is IBS Awareness Month in many countries. During this month every year, increased and very needed attention is given to IBS and the experiences of those of us who live with it. Join IBS Impact, other affected people, families, friends, IBS and functional…
April is IBS Awareness Month in many countries. During this month every year, increased and very needed attention is given to IBS and the experiences of those of us who live with it. Join IBS Impact, other affected people, families, friends, IBS and functional…
Alfasigma USA, Inc. the United States distributor of tegaserod, brand name Zelnorm, which is a prescription medication for some women with IBS with constipation (IBS-C), has announced that as of June 30, 2022, it is no longer providing this medication. Alfasigma’s press release states…
The American Journal of Gastroenterology has published the American College of Gastroenterology’s newly updated guidelines for the management of irritable bowel syndrome (IBS) in its December 2020 issue. Seven named authors from the fields of gastroenterology and gastrointestinal health psychology, represent five United States…
Beginning in 2007, the International Foundation for Gastrointestinal Disorders (IFFGD) began conducting a multi-year comprehensive survey of people with IBS, their experiences and unmet needs. This survey attracted a large number of responses internationally and its insights have been important contributions to IBS research,…
This past week, the U.S Food and Drug Administration (FDA) approved the sale and distribution of a new medication for irritable bowel syndrome with constipation (IBS-C), tenapanor, to be known by the brand name Ibsrela. Tenapanor, a 50 mg. daily oral medication is approved…
The U.S Food and Drug Administration (FDA) has approved marketing of the IB-Stim device, for use in adolescents, ages 11-18, with functional gastrointestinal pain related to irritable bowel syndrome (IBS). IB-Stim, developed by Innovative Health Solutions in Indiana, is a small nerve stimulator device…
The Journal of the Canadian Association of Gastroenterology has newly published guidelines for the management of irritable bowel syndrome (IBS) in adults in its April 2019 issue. Twelve named authors from the fields of gastroenterology, health psychology and primary care, represent six Canadian universities…
U.S. FDA Approves Return of Tegaserod (Zelnorm) to U.S. Market for Some Women with IBS-C, April 2019
At the end of March 2019, the U.S Food and Drug Administration (FDA) approved the reintroduction of tegaserod (brand name Zelnorm), an oral medication for irritable bowel syndrome with constipation (IBS-C) to the U.S., only for women without risk factors for or history of…
According to news releases, the Canadian branch of Lupin Pharmaceuticals, the distributor of Rifaximin, recently announced that Health Canada, the Canadian drug regulatory agency, has approved its use for irritable bowel syndrome with diarrhea (IBS-D). Rifaximin, which is manufactured by Salix Pharmaceuticals in the…